Journal Article

DZNE-2021-00032

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds

Brockmann, K. (First author)DZNE*

2020
Frontiers Media Lausanne

This record in other databases:    

Please use a persistent id in citations: doi:10.3389/fcell.2020.562522

Abstract: With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically associated with the alpha-synucleinopathies: Parkinson’s disease and dementia with Lewy bodies.

---

Contributing Institute(s):

1. Parkinson Genetics (AG Gasser 1)

Research Program(s):

1. 345 - Population Studies and Genetics (POF3-345) (POF3-345)

Appears in the scientific report 2020

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---